1. Shortening New Drug Development Timelines and Saving R&D Expenses — MTAM/Screen/Trial (Matching Drugs to Cancer Patients): This service focuses on assisting CRO clients (pharmaceutical companies) by providing unique and innovative MTAM/HFA services, enhancing pharmacodynamic evaluation statistics and high-efficiency screening platforms, effectively shortening preclinical and clinical Phase I and Phase II timelines, saving approximately 80% of new drug development costs, while simultaneously tracking and analyzing preclinical trial data.

2. Screening Anticancer Drugs for Cancer Patients — MTAM/Select (Matching Patients to Cancer Drugs): This service focuses on rapid screening of anticancer drugs for cancer patient populations with an accuracy rate of over 90%, effectively enabling oncologists to promptly administer the most effective medication to each cancer patient, thereby improving treatment efficacy. Preventing the waste of national social security resources, reducing the financial burden of medical care on patients' families, and fighting for higher survival rates for cancer patients are precisely the original intentions behind the national promotion of personalized precision medicine.

1. Precision Medicine: Chang-An-Shih® FloraUp®, Zhen-An-Shih, BRCA Gene Testing and Analysis (aBRCA), WES (Whole Exome Sequencing), HorSeq®, HorTarget®, aBEST® (Liquid Biopsy), Ai-An-Shih® (Cancer Drug Gene Testing)
2. Dietary Supplements: FloraUP ALLBIO LIFE, INC. Specially Formulated Probiotics, Flora8 ALLBIO LIFE, INC. Specially Formulated Probiotics, FloraZ ALLBIO LIFE, INC. EZ PLUS Specially Formulated Probiotics, FloraG Golden Ginger Probiotics, FloraC Beauty C Specially Formulated Probiotics, FloraS Specially Formulated Probiotics, FiberUPgrade ALLBIO LIFE, INC. Slim Botanical Extract, ALLBIO LIFE, INC. Specially Formulated Probiotics Gift Set
3. Pet Health Examination and Analysis: Chong-An-Shih
4. Research Reagents and Consumables

1. Circulating Tumor Cell (CTC) Detection Services: Non-invasive early cancer screening and recurrence monitoring, providing additional cancer risk indicators and information.
2. Genetic Testing Services: To understand the status of tumor gene mutations in cancer tissues, gain a deeper understanding of the causes of cancer development and the correlation between cancer progression and genes, thereby assisting physicians in formulating appropriate treatment strategies.
3. Development of Research Projects for Clinical Application: Translating research findings into clinical applications through the development of cutting-edge research projects and the design of microfluidic chip instruments.

We are the first commercial platform to utilize a Patient-Derived Explants (PDEs) platform to evaluate and select cancer immunotherapy responses by developing single-cell functional multi-omics analysis modules. Cell Envision accelerates the identification of disease etiology and discovery in oncology by revealing the true functional biology of each patient's cells.